Evidence map›Paper›PMID 32159801›Full record

ArticleRheumatology (Oxford, England)2020

Characterizing infection in anti-neutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, matched-cohort data linkage study.

Shifa H Sarica, Neeraj Dhaun, Jan Sznajd, John Harvie, John McLaren, Lucy McGeoch, Vinod Kumar, Nicole Amft, Lars Erwig, Angharad Marks and 2 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Glucocorticoid-free treatment of severe ANCA-associated vasculitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Shifa H SaricaAberdeen Centre for Health Data Science, University of Aberdeen, Aberdeen, UK.
Neeraj DhaunQueen's Medical Research Institute, University/British Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, UK.
Jan SznajdDepartment of Rheumatology, Raigmore Hospital, Inverness, UK.
John HarvieDepartment of Rheumatology, Raigmore Hospital, Inverness, UK.
John McLarenFife Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, UK.
Lucy McGeochCentre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK.
Vinod KumarRheumatology Department, Ninewells Hospital, Dundee, UK.
Nicole AmftGlaxoSmithKline, Medicines Research Centre, Stevenage, UK.
Lars ErwigGlaxoSmithKline, Medicines Research Centre, Stevenage, UK.
Angharad MarksMorriston Hospital Renal Unit, Abertawe Bro Morgannwg University Health Board, Swansea, UK.
Corri BlackAberdeen Centre for Health Data Science, University of Aberdeen, Aberdeen, UK.
Neil BasuInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
GlaxoSmithKline (United Kingdom) · GBRaigmore Hospital · GBUniversity of Aberdeen · GBBritish Heart Foundation · GBGlasgow Royal Infirmary · GBNinewells Hospital · GBSwansea Bay University Health Board · GBUniversity of Glasgow · GBWhyteman’s Brae Hospital · GB

Funding

Wellcome TrustWellcome Trust MR/K007017/1
6 · The paper itself

Abstract

objectivesInfection exerts a major burden in ANCA-associated vasculitis (AAV), however, its precise extent and nature remains unclear. In this national study we aimed to longitudinally quantify, characterize and contextualize infection risk in AAV.

methodsWe conducted a multicentre matched cohort study of AAV. Complementary data on infections were retrieved via data linkage with the population-based Scottish microbiological laboratory, hospitalization and primary care prescribing registries.

resultsA total of 379 AAV patients and 1859 controls were followed up for a median of 3.5 years (interquartile range 1.9-5.7). During follow-up, the proportions of AAV patients with at least one laboratory-confirmed infection, severe infection and primary care antibiotic prescription were 55.4%, 35.6% and 74.6%, respectively. The risk of infection was higher in AAV than in matched controls {laboratory-confirmed infections: incidence rate ratio [IRR] 7.3 [95% confidence interval (CI) 5.6, 9.6]; severe infections: IRR 4.4 [95% CI 3.3, 5.7]; antibiotic prescriptions: IRR 2.2 [95% CI 1.9, 2.6]}. Temporal trend analysis showed that AAV patients remained at a higher risk of infections throughout the follow-up period, especially year 1. Although the Escherichia genus was the most commonly identified pathogen (16.6% of AAV, 5.5% of controls; P < 0.0001), AAV patients had the highest risk for Herpes [IRR 12.5 (95% CI 3.7, 42.6)] and Candida [IRR 11.4 (95% CI 2.4, 55.4)].

conclusionAAV patients have up to seven times higher risk of infection than the general population and the overall risk remains significant after 8 years of follow-up. The testing of enhanced short- to medium-term prophylactic antibiotic regimes should be considered.

Indexed as

AgedAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBacterial InfectionsCandidiasisCase-Control StudiesChurg-Strauss SyndromeFemaleGranulomatosis with PolyangiitisHerpesviridae InfectionsHumansInformation Storage and RetrievalLongitudinal StudiesMaleMicroscopic PolyangiitisMiddle AgedRegistrieseosinophilic granulomatosis with polyangiitisgranulomatosis with polyangiitisinfectionslongitudinal studymicroscopic polyangiitis

Identifiers

PMID32159801
PMCPMC7516107
OpenAlexW3012521203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.